Mitral Kapak Prolapsusu İle Otoimmünite Arasında İlişki Var Mı? Çocuk Olguların Değerlendirilmesi

Year 2011, Volume: 5 Issue: 3, 156 - 161, 01.06.2011

Utku Arman Örün Mahmut Keskin Önder Doksöz Selmin Karademir Vehbi Doğan Özben Ceylan Senem Özgür Osman Yılmaz Burhan Öcal Filiz Şenocak Ülker Ertan

Abstract

Amaç: Mitral kapak prolapsusu (MVP) sık rastlanan bir kalp kapak hastalığıdır. Etyopatogenezinde genetik ve nöroendokrin faktörler yanısıra otoimmünitenin de rol aldığı düşünülmektedir. Çalışmamızda mitral valv prolapsuslu hastalarda otoimmün belirteçlerin taranarak, otoimmünitenin rolü incelenmek istenmiştir.Gereç ve yöntem: Mayıs 2009-Aralık 2009 tarihleri arasında Dr. Sami Ulus Kadın Doğum, Çocuk Sağlığı ve Hastalıkları Eğitim ve Araştırma Hastanesi Pediatrik Kardiyoloji bölümünde MVP tanısı ile takip edilen 38 olgu hasta grubu ve 38 sağlıklı olgu kontrol grubu olarak çalışmaya alındı. Hasta ve kontrol grubunda akut faz reaktanları, biyokimyasal testler, serum immunoglobulin düzeyleri, kompleman 3 ve 4, antinükleer antikorlar, antikardiyolipin ve antifosfolipid antikorları, tiroid otoantikorları, romatoid faktör tetkikleri uygulandı. Elektrokardiyografi ( EKG) ve telekardiyografi çekildi, ekokardiyografik inceleme yapıldı.Bulgular: Hasta ve sağlıklı gruplar karşılaştırıldığında otoimmün belirteçler arasında istatistiksel olarak anlamlı fark bulunamadı (p>0.05). Hasta grubundaki 4 olguda ( 3 parsiyel, 1 selektif), kontrol grubundaki 2 olguda (2 parsiyel ) immünglobulin A (IgA) düzeyi düşük bulundu, ancak istatistiksel olarak anlamlı değildi (p>0,05).Sonuç: Çalışmamızda MVP ve otoimmün belirteçler arasında istatistiksel olarak anlamlı bir sonuç elde edilemedi. Ancak IgA eksikliğinin hasta grubunda kontrol grubuna göre daha fazla olduğunu gözledik. İstatistiksel olarak anlamlı olmasa da IgA eksikliği saptanan MVP’li çocuk hastaların ileri yaşlarda otoimmünite gelişebilme olasılığı yönünden izlenmesi gerektiği sonucuna varıldı.

Keywords

Mitral kapak prolapsusu, otoimmünite, IgA eksikliği, çocukluk çağı

DOES MITRAL VALVE PROLAPSE HAVE RELATION WITH AUTOIMMUNITY OR NOT? EVALUATION OF PEDIATRIC CASES

Abstract

Aim: Mitral valve prolapse (MVP) is a common cardiac valvular disease. Besides genetic and neuroendocrine factors, autoimmunity is thought to play a role in its pathogenesis. In this study, we aimed to evaluate the role of autoimmunity in development of MVP through the screening of certain markers related with autoimmunity. Materials and methods: Between May 2009 and December 2009; a total of 38 patients followed with the diagnosis of MVP in the Pediatric Cardiology Department of Dr. Sami Ulus Maternity and Children’s Education and Research Hospital and a control group consisting of 38 healthy children were included in the study. Acute phase reactants, biochemical tests, levels of serum immunoglobulin, complement levels, antinuclear antibodies, antithyroid antibodies, rheumatoid factor, anticardiolipin, and antiphospholipid antibodies were all determined. Electrocardiography, telecardiography, and echocardiography were also performed in all cases. Results: In the comparison of two groups, no statistically significant difference was shown concerning autoimmunity markers (p>0.05). Four children in the patient group (3 with partial and one with selective Ig A deficiency) and 2 children in the control group (2 with partial Ig A deficiency) had low Ig A levels, whereas the difference between two groups were not statistically significant (p>0.05). Conclusion: In our study, no significant correlation was found between MVP and autoimmune markers. However, we observed that Ig A deficiency is more frequent in the patient group than in the control group. In spite of the statistically non-significant association between MVP and autoimmunity markers, we conclude that children with MVP having Ig A deficiency should be followed up for the development of autoimmune disoredrs in their future life

Keywords

Mitral valve prolapse, autoimmunity, IgA deficiency, childhood

References

• Babaoğlu K, Karaçayır N, Binnetoğlu K. Çocuklarda Mi- tral Kapak Prolapsusu: 113 olgunun klinik özellikleri. Türk Ped. Arsivi 2009;44(2):57-61.
• Boundaulas H, Wooley FC. The floppy mitral valve, mitral valve prolapse, and mitral valvular regurgitation. In: Allen HD, Driscoll DJ (eds). Moss and Adams’ Heart Disease in Infants, Children and Adolescents. Balt imore: Lippincott Williams & Wilk ins; 2008:947-69
• Nadas AS. Mitral valve prolapse. In: Lock JE, Fyler DC (eds). Nadas’ Pediatric Cardiology. P hiladelphia: WB Saunders Co; 2006:701-4.
• Evangelopoulos ME, Alevizaki M, Toumanidis S, Piperin- gos G, Mavrikakis M, Sotou D, et al. Mitral valve prolapse in autoimmune thyroid disease: an index of systemic auto- immunity? Thyroid 1999;9(10):973-7.
• Brauman A, Algom M, Gilboa Y, Ramot Y, Golik A, Stryjer D. Mitral valve prolapse in hyperthyroidism of two differ- ent origins. Br Heart J 1985;53(4):374-7.
• Barzizza F, Venco A, Grandi AM, Finardi G. Mitral valve prolapse in systemic lupus erythematosus. Clin Exp Rheu- matol 1987;5(1):59-62.
• Comens SM, Alpert MA, Sharp GC, Pressly TA, Kelly DL, Hazelwood SE, et al. Frequency of mitral valve prolapse in systemic lupus erythematosus, progressive systemic scle- rosis and mixed connective tissue disease. Am J Cardiol 1989;63(5):369-70
• Bragagni G, Brogna R, Franceschetti P, Zoli G. Cardiac in- volvement in Crohn’s disease: echocardiographic study. J Gastroenterol Hepatol 2007;22(1):18-22.
• Evangelopoulos ME, Toumanidis S, Sotou D, Evangelo- poulos C, Mavrikakis M, Alevizaki M, Dimopoulos MA. Mitral valve prolapse in young healthy dividuals. An early index of autoimmunity? Lupus 2009;18(5):436-40.
• Nishimura, Richard L. Page, and Barbara Riegel Jona- than L. Halperin, Loren F. Hiratzka, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease J Am Coll Cardiol 2006;48;11-2.
• Grifka RG, Vincent JA. Abnormalities of the left atrium and mitral valve, including mitral valve prolapse. In: Gar- son A, Bricker JT, Fisher D, Neish SR (eds). The Science and Practice of Pediatric Cardiology. 2nd ed. Pennsylvania: Williams and Wilkins; 1998:1277-301.
• Savage DD, Garrisson RJ, Devereux RB, Castelli WP, An- derson SJ, Levy D, et al. Mitral valve prolapse in the gener- al population. 1. Epidemiologic features: The Framingham Study. Am Heart J 1983;106(3):571-6.
• Bisset III GS, Schwartz DC, Meyer RA, James FW, et al. Clinical spectrum and long-term follow-up of iso- lated mitral valve prolapse in 119 children. Circulation 1980;62(2):423-9.
• Warth DC, King ME, Cohen JM, Tesoriero VL, Marcus E, Weyman AE. Prevalence of mitral valve prolapse in normal children. J Am Coll Cardiol 1985;5(5):1173-7.
• Roberts WC. Valvular heart disease of congenital origin. In: Frankl WS, Brest NA (eds). Valvular Heart Disease: Comprehensive Evaluation and Treatment. Philadelphia: FA Davis; 1993:25-9
• Levy D, Savage D. Prevalence and clinical features of mi- tral valve prolapse. Am Heart J 1987;113(5):1281-90.
• Bowen J, Boudoulas H, Wooley C. Cardiovascular disease of connective tissue origin. Am J Med 1987;82(3):481-8.
• Sablayrolles B, Dutau G, Rochiccioli P. Basedow’s disease, Marian’s disease and mitral valve prolapse. Presse Med 1985;14(10):598-9.
• Channick BJ, Aldin EV, Marks AD, Denenberg BS, Mc- Donough MT, Chakko CS, et al. Hyperthyroidism and mi- tral valve prolapse. N Engl J Med 1981;305(9):497-500.
• Kahaly G, Mohr-Kahaly S, Beyer J. Prevalence of myxo- matous mitral valve prolapse in patients with Lymphocytic Thyroiditis. Am J Cardiol 1995;76(17):1309-10.
• Evangelopoulos ME, Alevizaki M, Toumanidis S, Sotou D, Evangelopoulos CD, Koutras DA, et al. Mitral valve pro- lapse in systemic lupus erythematosus patients: clinical and immunological aspects. Lupus 2003;12(4):308-11.
• Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, et al. Association of antibodies against phospho- lipids with heart valve disease in systemic lupus erythema- tosus. Lancet 1990;335(8705):1541-4.
• Blohorn A, Guegan-Massardier E, Triquenot A, Onnient Y, Tron F, Borg JY, et al. Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: a descriptive study of 139 patients. Cerebrovasc Dis 2002;13(3):156-62.
• Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 2005;20(2):105-12.
• Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Mof- fatt K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995 15;86(10):3685- 91.
• Evangelopoulos ME, Toumanidis S, Sotou D, Evangelo- poulos C, Mavrikakis M, Alevizaki M, et al. Mitral valve prolapse in young healthy individuals. An early index of autoimmunity?. Lupus 2009;18(5):436-40.
• Edwards E, Razvi S, Cunningham-Rundles C. IgA defi- ciency: clinical correlates and responses to pneumococcal vaccine. Clin Imm 2004;111(1):93-7.
• Jorgensen GH, Thorsteinsdottir I, Gudmundsson S, Ham- marstrom L, Ludviksson BR. Familial aggregation of IgAD and autoimmunity. Clin Immunol 2009;131(2):233-9.
• Yel L. Selective IgA deficiency. J Clin Immunol. 2010;30(1):10-6.